Lantheus Holdings, Inc. (NASDAQ:LNTH) Director Mary Anne Heino Sells 26,066 Shares

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director now directly owns 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mary Anne Heino also recently made the following trade(s):

• On Thursday, March 13th, Mary Anne Heino sold 2 shares of Lantheus stock. The shares were sold at an average price of $100.13, for a total value of $200.26.

Lantheus Trading Up 1.5%

Lantheus stock traded up $1.22 on Friday, reaching $81.55. 924,397 shares of the stock were exchanged, compared to its average volume of 1,003,870. Lantheus Holdings, Inc. has a twelve month low of $73.11 and a twelve month high of $126.89. The firm has a fifty day moving average price of $90.26 and a two-hundred day moving average price of $91.74. The stock has a market cap of $5.64 billion, a PE ratio of 13.57 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. During the same quarter in the previous year, the company earned $1.69 EPS. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. Equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Institutional Trading of Lantheus

Several hedge funds and other institutional investors have recently bought and sold shares of LNTH. Blue Trust Inc. lifted its position in Lantheus by 38.1% in the fourth quarter. Blue Trust Inc. now owns 1,981 shares of the medical equipment provider's stock worth $177,000 after purchasing an additional 547 shares during the period. KBC Group NV boosted its holdings in Lantheus by 55.4% in the fourth quarter. KBC Group NV now owns 2,950 shares of the medical equipment provider's stock valued at $264,000 after acquiring an additional 1,052 shares during the last quarter. abrdn plc raised its position in shares of Lantheus by 18.7% during the 4th quarter. abrdn plc now owns 7,159 shares of the medical equipment provider's stock valued at $640,000 after acquiring an additional 1,127 shares during the last quarter. Retirement Systems of Alabama boosted its holdings in Lantheus by 128.9% during the fourth quarter. Retirement Systems of Alabama now owns 193,101 shares of the medical equipment provider's stock worth $17,275,000 after buying an additional 108,759 shares during the last quarter. Finally, Stratos Wealth Advisors LLC increased its stake in Lantheus by 1.9% in the fourth quarter. Stratos Wealth Advisors LLC now owns 22,269 shares of the medical equipment provider's stock valued at $1,992,000 after purchasing an additional 406 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on LNTH shares. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. B. Riley decreased their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Finally, Truist Financial cut their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $132.67.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.